Martin Kolar

Martin Kolar

Auto-generated profile, based on publicly available information

Martin Kolar

IBD Clinical and Research Centre, Iscare a.s., Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2016 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
PDF file
KFKlaudia Farkas
Klaudia Farkas
MRMariann Rutka
Mariann Rutka
PGPetra A. Golovics
Petra A. Golovics
ZVZsuzsanna Végh
Zsuzsanna Végh
BLBarbara D. Lovász
Barbara D. Lovász
TMTamás Molnár
Tamás Molnár
Introduction. CT-P13 is the first biosimilar to infliximab that was approved for the same indications as its originator infliximab. No data is available on the effect of infliximab biosimilar on mucosal healing. The aim of this study was to evaluate the efficacy of CT-P13 induction therapy on mucosal healing in patients with ulcerative colitis (UC). Patients and methods. UC patients, who received CT-P13 therapy from its local introduction at three Hungarian and one Czech IBD centres, were prospectively enrolled. Sigmoidoscopy was performed after the end of the induction therapy at week 14. Mucosal healing was defined as Mayo endoscopic subscore 0 or 1. Complete mucosal healing was defined as Mayo endoscopic subscore 0. Trough level of CT-P13 was measured at week 14. Results. Sixtythree UC patients who underwent CT-P13 induction therapy were enrolled in the study. Indication of the therapy was acute, severe flare up and chronic, refractory activity in 24 and 39 patients. Cumulative clinical response and steroid-free remission at week 14 were achieved in 82.5% and 47.6% of the patients. Sigmoidoscopy revealed steroid-free mucosal healing in 47.6% of the patients, complete mucosal healing was present in 27%. Mayo endoscopic subscore decreased significantly at week 14 compared to baseline. Trough levels of infliximab correlated with mucosal healing. Conclusion. This was the first study examining the efficacy of CT-P13 induction therapy on mucosal healing in UC. Our results indicate that mucosal healing is achieved in two thirds of UC patients by the end of the induction treatment with CT-P13.

1 December 2017 in Practical Laboratory Medicine
Verified
Journal Article
Open access
KMKarin Malíčková
Karin Malíčková
IFIrena Francová
Irena Francová
MLMilan Lukáš
Milan Lukáš
MKMartin Kolář
Martin Kolář
EKEva Králíková
Eva Králíková
TZTomáš Zima
Tomáš Zima
Human zonulin is a protein that increases permeability in the epithelial layer of the small intestine by reversibly modulating the intercellular tight junctions. There is not sufficient information available about zonulin's participation in inflammatory bowel diseases (IBD). The aim of this study was therefore to investigate fecal and serum zonulin in IBD patients and its relation to the disease localization, behavior and smoking status. Forty IBD patients and forty healthy persons were examined for fecal and serum zonulin concentrations by competitive ELISA (DRG International Inc). Values were correlated to IBD type, localization and behavior, and smoking. Serum and fecal zonulin were significantly higher in patients with Crohn's disease compared to ulcerative colitis (p = 0.038 for fecal zonulin, and p = 0.041 for serum zonulin concentrations). No association of serum or fecal zonulin was found with respect to IBD localization and behavior. The only difference was found with respect to smoking. Both the IBD cohort and healthy smokers showed significantly higher fecal zonulin levels (median 203 ng/mL) compared to non-smokers (median 35.8 ng/mL), p < 0.001. Fecal and serum zonulin levels are elevated in patients with active Crohn's disease but not with ulcerative colitis. High fecal zonulin levels in smokers irrespective of IBD point to the significant and undesirable up-regulation of gut permeability in cigarette smokers.

2 September 2015 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
MBMartin Bortlik
Martin Bortlik
DDDana Duricova
Dana Duricova
NMNadezda Machkova
Nadezda Machkova
VHVeronika Hruba
Veronika Hruba
MLMartin Lukas
Martin Lukas
MLMilan Lukas
Milan Lukas
(2016). Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation. Scandinavian Journal of Gastroenterology: Vol. 51, No. 2, pp. 196-202. doi: 10.3109/00365521.2015.1079924

6 January 2020 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
MLMartin Lukas
Martin Lukas
KMK Malickova
K Malickova
MKM Kolar
M Kolar
MBM Bortlik
M Bortlik
MVM Vasatko
M Vasatko
MLMilan Lukas
Milan Lukas
Patients’ perspectives after switching from originator to biosimilar adalimumab have yet to be assessed. We evaluated the efficacy of switching from the originator adalimumab to a biosimilar compound [SB5] in patients with inflammatory bowel disease [IBD]. Data on IBD patients who were switched from the originator to biosimilar adalimumab [SB5] at IBD Center ISCARE were analysed. Disease activity was assessed using standard clinical indices (Harvey-Bradshaw index [HBI] for Crohn’s disease [CD] and partial Mayo score for ulcerative colitis [UC]), and laboratory parameters (C-reactive protein [CRP] and faecal calprotectin [FC]). Trough levels and anti-drug antibodies were measured. Patients were evaluated 10 weeks [W10] after the switch, and results were compared with the control group of patients on originator compound. A total of 93 patients switched to biosimilar adalimumab were included [CD 86%] and were matched to 93 controls for age, gender, diagnosis, and disease activity. There was no difference in the disease activity in either SWITCH or ORIGINATOR cohorts between Weeks 0 and 10. Similarly, no difference was found between cohorts at both prespecified time points. Moreover, no significant differences in CRP or FC concentrations were seen between W0 and W10 either in the SWITCH, or in the ORIGINATOR cohort [p >0.05]. Adalimumab serum trough levels remained stable after the switch. No new safety signals were detected. Our study confirmed that switching IBD patients from the originator adalimumab to a biosimilar compound [SB5] does not affect treatment efficacy.

1 February 2017 in Digestive Diseases
Verified
Journal Article
Closed access
MKM. Kolar
M. Kolar
DDD. Duricova
D. Duricova
MBM. Bortlik
M. Bortlik
VHV. Hruba
V. Hruba
NMN. Machkova
N. Machkova
MLMilan Lukas
Milan Lukas
Background: The evidence on the efficacy and safety of biosimilar infliximab (IFX) in patients with inflammatory bowel diseases (IBD) is sparse. Methods: Consecutive IBD patients visiting our centre were included. One cohort composed of prospectively followed patients who were switched from original to biosimilar IFX between January and March 2015. The second cohort included retrospectively assessed anti-tumor necrosis factor α-naïve patients who started therapy between January 2015 and January 2016. Disease activity was assessed using standard clinical indices, endoscopic evaluation, and laboratory parameters (blood count, C-reactive protein (CRP) and fecal calprotectin (FC)). Trough levels and anti-drug antibodies (ATIs) were also measured. Patients were evaluated 56 weeks (W56) after switch and at week 14 (W14) and week 46 (W46) in the naïve cohort. Results: Seventy-four IBD patients were switched to biosimilar IFX and 119 naïve patients newly initiated therapy with the preparation. Disease activity remained stable in a majority of switched patients (remission at week 0 (W0) vs. W56: 72.2 vs. 77.8%; median difference of both Harvey-Bradshaw index and Simple Clinical Colitis Activity Index between W0 and W56 was 0). When W0 and W56 were compared, no significant difference in CRP (4.3 ± 8.0 vs. 3.3 ± 3.8 mg/l; p = 0.89) and FC (135 ± 153 vs. 199 ± 225 µg/g; p = 0.17) was observed. In total, 92% of Crohn's disease (CD) and 83% of ulcerative colitis (UC) patients responded to induction therapy (W14) with biosimilar IFX. At W46, the response rate was 86% in CD and 64% in UC. Moreover, half of UC patients experienced mucosal healing at W14 and improvement of perianal disease occurred in 95% of CD at W46. In this cohort, clear steroid-sparing effect was observed. No increase in immunogenicity was found in switched patients (ATI positivity: 9.5 vs. 6.0%, p = 0.54) and the type and frequency of adverse events were comparable to the original preparation in both cohorts. Conclusion: Switching of IBD patients from original to biosimilar IFX is effective and safe.

30 January 2020 in Intestinal Research
Verified
Journal Article
Open access
PDF file
SPSang Hyoung Park
Sang Hyoung Park
JPJae Cheol Park
Jae Cheol Park
MLMilan Lukas
Milan Lukas
MKMartin Kolar
Martin Kolar
ELEdward Loftus
Edward Loftus
The inflammatory bowel diseases (IBD), which consist of Crohn's disease and ulcerative colitis, are chronic, incurable immunemediated inflammatory disorders of the intestine. As IBD incidence continues to increase globally and its mortality is low, prevalent cases of IBD are rapidly increasing, thereby leading to a substantial increase in health care costs. Although the introduction of biologic agents for IBD management has revolutionized the armamentarium of IBD therapy, the high cost of this therapy is concerning. With the expirations of patents for existing biologic agents (originals), biosimilars with cheaper costs have been highlighted in the field of IBD. Despite concerns regarding their short- and long-term efficacy, safety, immunogenicity, and interchangeability, increasing evidence via prospective observations and phase III or IV clinical trials, which aim to prove the "biosimilarity" of biosimilars to originals, has partly confirmed their efficacy, safety, and interchangeability. Additionally, although patients and physicians are reluctant to use biosimilars, a positive budget impact has been reported owing to their use in different countries. In the near future, multiple biosimilars with lower costs, and efficacy and safety profile similar to originals, could be used to treat IBD; thus, further consideration and knowledge dissemination are warranted in this new era of biosimilars.